Claims for Patent: 11,707,464

Summary for Patent: 11,707,464

Title:	Methods of treating heavy menstrual bleeding
Abstract:	The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.
Inventor(s):	Kristof Chwalisz, Laura A. Williams, Rita I. Jain, Janine D. North, Juki Wing-Keung Ng
Assignee:	AbbVie Inc
Application Number:	US17/455,652
Patent Claims:	1. A method of managing moderate to severe pain associated with endometriosis in a premenopausal adult human female patient, the method comprising: oral administration to the patient of 150 mg of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid, administered as a sodium salt (“elagolix”), and continuing said oral administration once daily for 24 months to manage the moderate to severe pain associated with endometriosis; wherein the method reduces dysmenorrhea and non-menstrual pelvic pain in the patient without an increase in use of a concomitant medication for the treatment of endometriosis-related pain by the patient; wherein the patient exhibits no more than a 2% reduction from baseline in lumbar spine BMD at six months and no more than an 8% reduction from baseline in lumbar spine bone mineral density (BMD) at 24 months; and wherein the method does not comprise administration of an add-back therapy. 2. The method of claim 1, wherein the concomitant medication for the treatment of endometriosis-related pain is an analgesic. 3. The method of claim 2, wherein the analgesic is an anti-inflammatory drug or an opioid. 4. The method of claim 1, wherein the patient does not have osteoporosis. 5. The method of claim 1, wherein the method further comprises administration of supplementary calcium, vitamin D, or a combination thereof. 6. The method of claim 1, wherein BMD in the patient has been assessed prior to said oral administration. 7. A method of managing moderate to severe pain associated with endometriosis in a premenopausal adult human female patient for 24 months, the method comprising: oral administration to the patient of 150 mg of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid, administered as a sodium salt (“elagolix”), and continuing said oral administration once daily for 24 months, wherein said once daily administration does not exceed 24 months to limit the extent of bone mineral density (BMD) loss associated with elagolix exposure; wherein the method reduces dysmenorrhea and non-menstrual pelvic pain in the patient; and wherein the method does not comprise administration of an add-back therapy. 8. The method of claim 7, wherein the method reduces dysmenorrhea and non-menstrual pelvic pain in the patient without an increase in use of a concomitant medication for the treatment of endometriosis-related pain by the patient. 9. The method of claim 8, wherein the concomitant medication for the treatment of endometriosis-related pain is an analgesic. 10. The method of claim 9, wherein the analgesic is an anti-inflammatory drug or an opioid. 11. The method of claim 7, wherein the patient does not have osteoporosis. 12. The method of claim 7, wherein the method further comprises administration of supplementary calcium, vitamin D, or a combination thereof. 13. The method of claim 8, wherein BMD in the patient has been assessed prior to said oral administration. 14. The method of claim 7, wherein the patient exhibits no more than a 2% reduction from baseline in lumbar spine BMD at six months. 15. The method of claim 7, wherein the patient exhibits no more than an 8% reduction from baseline in lumbar spine BMD at 24 months. 16. A method of managing moderate to severe pain associated with endometriosis in a premenopausal adult human female patient with no known history of osteoporosis for 24 months, the method comprising: determining that the patient has no known history of osteoporosis, oral administration to the patient with no known history of osteoporosis of 150 mg of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid, administered as a sodium salt (“elagolix”), and continuing said oral administration once daily for 24 months to manage the moderate to severe pain associated with endometriosis; wherein the method reduces dysmenorrhea and non-menstrual pelvic pain in the patient; and wherein the method does not comprise administration of an add-back therapy. 17. The method of claim 16, wherein the method reduces dysmenorrhea and non-menstrual pelvic pain in the patient without an increase in use of a concomitant medication for the treatment of endometriosis-related pain by the patient. 18. The method of claim 17, wherein the concomitant medication for the treatment of endometriosis-related pain is an analgesic. 19. The method of claim 18, wherein the analgesic is an anti-inflammatory drug or an opioid. 20. The method of claim 16, wherein the method further comprises administration of supplementary calcium, vitamin D, or a combination thereof. 21. The method of claim 16, wherein BMD in the patient has been assessed prior to said oral administration. 22. A method of managing moderate to severe pain associated with endometriosis in a premenopausal adult human female patient with a history of low-trauma fractures or a history of a condition associated with a decrease in bone mineral density (BMD) for 24 months, the method comprising: providing a dosage form comprising 150 mg or 200 mg of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid as a sodium salt, determining that the patient has a history of low-trauma fractures or a history of a condition associated with a decrease in BMD, selecting a dosing regimen suitable to mitigate further decreases in BMD in the patient, wherein the selected dosing regimen comprises once daily oral administration to the patient of the dosage form comprising 150 mg of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid as a sodium salt (“elagolix”), and orally administering elagolix to the patient with a history of low-trauma fractures or a history of a condition associated with a decrease in BMD according to the selected dosing regimen for 24 months to manage the moderate to severe pain associated with endometriosis; wherein the method reduces dysmenorrhea and non-menstrual pelvic pain in the patient; and wherein the method does not comprise administration of an add-back therapy. 23. The method of claim 22, wherein the method further comprises administration of supplementary calcium, vitamin D, or a combination thereof. 24. The method of claim 22, wherein the method further comprises assessing BMD in the patient prior to said oral administration. 25. The method of claim 22, wherein the method reduces dysmenorrhea and non-menstrual pelvic pain in the patient without an increase in use of a concomitant medication for the treatment of endometriosis-related pain by the patient. 26. The method of claim 25, wherein the concomitant medication for the treatment of endometriosis-related pain is an analgesic. 27. The method of claim 26, wherein the analgesic is an anti-inflammatory drug or an opioid.